Navigation Links
Hypertension Drug Adherence Associated with Fewer Hospitalizations and Lower Medical Costs but Increased Total Care Costs
Date:4/18/2012

SAN FRANCISCO, April 18, 2012 /PRNewswire/ -- Although adherence to hypertension medications was significantly associated with lower hospitalization rates, the total costs of care are higher for adherent patients than for patients who were deemed "non-adherent," according to a new study from pharmacy benefit manager Prime Therapeutics (Prime) that will be presented this week at the Academy of Managed Care Pharmacy (AMCP)'s 24th Annual Meeting & Expo in San Francisco.

The study found patients who were adherent to their hypertension medication had significantly associated lower hospitalization rates, although the higher drug expenses offset the lower medical costs resulting in a higher total cost of care. This result, according to the authors, differs from previous research showing lower hospitalization rates led to lower total costs, and may be due to population differences, including younger age.

Prime set out to compare one year of all-cause hospitalization rates, medical costs and pharmacy costs among patients who were adherent and non-adherent to hypertension medications. Working with the University of Minnesota College of Pharmacy, Data Intelligence Inc. of Eden Prairie, Minn., and one of its Blue Plan partners, Prime used retrospective data and medical claims from a commercially insured population of 3.6 million members with eligibility between 2007 and 2009.

Of the 91,931 members that fit the inclusion criteria of hypertensive patient, 66.4 percent (61,040) were adherent and 33.6 percent (30,891) were not. The adherent group was associated with a lower hospitalization rate (10.1 percent adherent vs. 11.1 percent non-adherent), lower medical costs ($7,124 adherent versus $7,441 non-adherent), higher pharmacy costs ($3,079 adherent versus $1,733 non-adherent) and high total cost of care ($10,203 adherent versus $9,174 non-adherent).

"Hypertension medication is associated with 20 percent lower hospitalization rate and lower medical costs," said Patrick Gleason, PharmD, director of clinical outcomes assessment at Prime. "Further research is needed, however, to assess the relationship between adherence and total costs of care."

Prime Therapeutics is a pharmacy benefit management company dedicated to providing innovative, clinically-based, cost-effective pharmacy solutions for clients and members. Providing pharmacy benefit services nationwide to nearly 20 million covered lives, its client base includes Blue Cross and Blue Shield Plans, employer and union groups, and third-party administrators. Headquartered in St. Paul, Minn., Prime Therapeutics is collectively owned by 13 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those Plans. Learn more at www.primetherapeutics.com.


'/>"/>
SOURCE Prime Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Local Medicare Contractors Expand Hypertension Coverage for CardioDynamics BioZ(R) ICG Technology
2. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
3. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
4. Uncontrolled Blood Pressure Highest Among Hispanics, Prompting New Hypertension Project in Miami
5. Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA)
6. Tracleer(R) Shows Clinical Benefit as Combination Therapy with Sildenafil for Pulmonary Arterial Hypertension
7. Results of TRIUMPH-1 Trial of Viveta in Pulmonary Arterial Hypertension to Be Announced Before Market Open on Thursday, November 1, 2007
8. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
9. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
10. Surface Logix Achieves Objectives With SLx-2101 in Phase 2a Clinical Trial in Hypertension
11. Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... develops, markets and sells medical devices and wearable sleep ... a strategic cooperation agreement with Hongyuan Supply Chain Management ... on June 20, 2016, to develop Dehaier,s new Internet ... agreement, Dehaier will leverage Hongyuan Supply Chain,s sales platform ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... today announced the appointment of Dr. Edward ... as a Non-Executive Director, effective June 23, 2016.Dr. ... Compensation and Nominations and Governance Committees.  As a ... will provide independent expertise and strategic counsel to ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 ... brings up a new, often overlooked aspect of head lice: the parasite’s ability to live ... not a common occurrence, but a necessary one in the event that lice have simply ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
Breaking Medicine News(10 mins):